1.	Phase III Randomized, Double-Blind Study of Daily x 14 Subcutaneous IL-11 vs Placebo for Severe Chemotherapy-Induced Thrombocytopenia (Summary Last Modified 06/98) Phase: Phase III Type: Supportive care Status: Closed Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENE-C9504-14, NCI-V96-0810
2.	Phase III Randomized Study of Interleukin-11 for Chemotherapy-Induced Thrombocytopenia in Patients With Solid Tumors or Lymphoma Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MRMC-CTCA-9705, GENE-C9707-14, NCI-V98-1440
3.	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00008, MC998C, P30CA015083, CDR0000068503, MAYO-MC998C, NCI-312, NCT00012298
4.	Phase II Study of Recombinant Human Interleukin-11 with Sargramostim (GM-CSF) for Acute Myeloid Leukemia Patients Receiving High-Dose Cytarabine During Induction and Consolidation Chemotherapy Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18-55 Sponsor: NCI Protocol IDs: E-3997, E3997
5.	Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Phase: Phase II Type: Supportive care Status: Completed Age: Not specified Sponsor: Other Protocol IDs: 2004-0113, NCT00493181
6.	Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Phase: Phase II Type: Treatment Status: Completed Age: 70 and under Sponsor: NCI, Other Protocol IDs: 1365.00, FHCRC-1365.00, NCI-G99-1622, CDR0000067395, NCT00004157